Trial Profile
Single Arm, Exploratory and Open Phase II Clinical Trial of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 08 Jul 2020 Planned End Date changed from 1 Nov 2019 to 1 Nov 2021.
- 08 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2018 New trial record